TD Cowen on Neurocrine Bio. (NBIX): 'R&D Day Highlights Uniquely Diversified And Robust Early Pipeline'
Tweet Send to a Friend
TD Cowen analyst Phil Nadeau reiterated a Buy rating and $200.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
